Effective laboratories are essential to tuberculosis control not only for diagnosing infectious cases, but also for detecting multidrug-resistant strains of TB. Since 2004 The Union's Laboratory Strengthening Programme has offered technical assistance, provided training and conducted operational research to strengthen national laboratory networks and improve their performance. Activities are conducted or coordinated primarily from the Mycobacteriology Unit of the Institute of Tropical Medicine in Antwerp, Belgium, where most of The Union laboratory staff is based.

Improving TB diagnosis with smear microscopy

Diagnosing infectious tuberculosis is the first step in TB control, and the most appropriate way to do this is to examine sputum smears under a microscope to detect acid-fast bacilli (AFB). Standardised techniques for smear microscopy have been available for many years, but the low detection rate of overall TB cases, not just the most infectious smear-positive ones, is recognised as one of the primary obstacles to successful worldwide TB control. New and far more efficient techniques such as LED fluorescence microscopy have come within reach of the low-income countries in recent years, and The Union is in the forefront to promote their widespread use and to solve the remaining logistical hurdles. Furthermore, with the spread of multidrug-resistant TB, laboratories are under increasing pressure to identify these bacilli by drug susceptibility testing (DST), and not to rely only on smear-microscopy.

Monitoring quality of drug susceptibility testing (DST)

As part of the WHO/Union Global Project for Surveillance of TB Drug Resistance, The Union's collaborating laboratory in Antwerp annually checks the quality of drug susceptibility testing among labs in the Supra-National TB Reference Laboratory Network or SRLN. National Reference Laboratories are also subject to quality controls, using the same panels, as well as rechecking of routine results. Since 2007, the test panels have included not only strains resistant to first-line drugs (multidrug-resistant TB or MDR-TB), but also second-line drugs (extensively drug-resistant TB or XDR-TB).

Testing for MDR- and XDR-TB

The Union has focused on building laboratories' effectiveness in identifying MDR- and XDR-TB since 2008. The goal has been to set up efficient surveillance of resistance to the main first- and second-line drugs, in addition to providing rapid and accurate diagnosis.

Building a network of expert laboratories

Another goal has been to expand the SRLN and increase its capacity to monitor and support national tuberculosis programmes (NTP) in middle- and low-income countries and help them achieve and maintain international quality standards. A new supra-reference laboratory (SRL) was thus created in Thailand in 2006, while Benin, Uganda and Tanzania were intensively tutored between 2007 and 2010. Other African national reference laboratories (NRL) that seemed eligible were evaluated by means of questionnaires, a few also were assessed on site, but no other good candidate SRL could be found. As a result of these efforts, finally only Uganda and Benin were accepted as candidate-SRL by WHO in 2011. Thanks to new USAID-funded TBCARE projects, both Uganda and Benin now benefit of additional tutoring towards laboratory accreditation, and they are being further prepared for their SRL duties. Hopefully they will acquire full SRL status soon. SRL consultants will then support selected countries in their region, reviewing a country's laboratory services, including the quality assessment systems, and making suggestions for improvement. They can also assist with individual training, monitoring progress, administering proficiency testing etc.